

Supplementary files

Appendix A: PAH targeted therapy related costs in the base-case analysis

Therapy type	Dosage	Price per person per year	Weighting factor according to proportional use
<i>Riociguat</i>	3 dd 1-2.5 mg	€ 34,055	0.4
<i>Macitentan</i>	1 dd 10 mg	€ 38,121	0.4
<i>Sildenafil</i>	3 dd 20 mg	€ 4,679	0.2
Weighted price for the mix of treatment groups *	-	€ 32,693	-

* Including double therapy (riociguat and macitentan) in 8% of patients after 2 years of treatment based on available literature, healthcare use in the VU Medical Center, and expert opinion [32, 33].

Note: Assumptions made concerning use of PAH targeted therapy: 1) PEA group: 25% of cases receive lifelong therapy two years after diagnosis[27-31]; 2) BPA group: 0.5 year of therapy in all patients (until first endovascular intervention), as well as in 60% of cases lifelong therapy; 3) PAH targeted therapy group: 100% of cases receive lifelong therapy; 4) no-treatment group: no therapy. Treatment with intravenous prostacyclin analogs has been left out of the cost-effectiveness model given the rare prescriptions in this setting. All costs were determined in euros for the year 2020.